Know Cancer

or
forgot password

A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors


Phase 1
18 Years
N/A
Not Enrolling
Both
Neoplasms

Thank you

Trial Information

A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors


Inclusion Criteria:



- Documented diagnosis of malignant solid tumor with measurable disease

- Life expectancy of at least 12 weeks

- ECOG (Eastern Cooperative Oncology Group) performance status of 0,1,or 2

Exclusion Criteria:

- Recent major surgery, radiation therapy or anti-cancer treatment

- History of any other prior malignancy within last 5 years

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the safety, tolerability and MTD (maximum tolerated dose) of MST-997.

Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Wyeth is now a wholly owned subsidiary of Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

3161K1-101

NCT ID:

NCT00277836

Start Date:

Completion Date:

Related Keywords:

  • Neoplasms
  • malignant tumor
  • Neoplasms

Name

Location

Austin, Texas  78705